affimed
announces
dosing
first
patient
phase
clinical
trial
cord
natural
killer
cells
combination
innate
cell
engager
first
kind
clinical
study
combining
natural
killer
nk
cell
product
innate
cell
engager
ice
study
investigates
nk
cells
preloaded
followed
subsequent
weekly
treatment
monotherapy
patients
recurrent
refractory
r
r
lymphomas
stable
preloading
nk
cells
enabled
high
affinity
binding
heidelberg
germany
october
affimed
nasdaq
afmd
company
committed
giving
patients
back
innate
ability
fight
cancer
today
announced
first
patient
successfully
dosed
allogeneic
cord
natural
killer
cbnk
cells
preloaded
moved
monotherapy
phase
treatment
cycle
therapy
developed
research
collaboration
university
texas
md
anderson
cancer
center
first
human
study
combine
nk
cell
product
antibody
whose
primary
mechanism
designed
specifically
bind
activate
nk
cells
tumors
cells
bispecific
fashion
novel
combination
approach
could
lay
groundwork
future
cellular
therapy
combinations
affimed
constructs
engaging
innate
immune
system
novel
promising
therapeutic
approach
oncology
products
designed
tap
thus
far
largely
remained
untapped
field
said
andreas
harstrick
chief
medical
officer
affimed
innate
immune
cells
takes
idea
step
potentially
intensifies
treatment
effect
especially
patients
impaired
immune
system
low
nk
cell
nk
cell
armed
designed
direct
nk
cells
tumor
site
order
target
cancer
cells
pursuant
study
design
dosing
preloaded
nk
cells
subsequently
administered
monotherapy
order
maintain
activation
infused
cbnk
cells
engage
patients
innate
immune
system
nk
cells
macrophages
distinct
feature
affimed
products
study
background
although
larger
numbers
nk
cells
patients
associated
better
outcomes
adoptive
transfer
nk
cells
shown
limited
clinical
benefit
target
recognition
cancers
nk
cells
remains
substantial
barrier
broad
application
nk
cell
therapy
preclinical
models
combining
adoptive
nk
cell
transfer
shown
enhance
efficacy
nk
cells
exhibited
much
longer
binding
nk
cells
compared
binding
monoclonal
antibodies
wildtype
adcc
enhanced
forming
basis
produce
stable
nk
cell
product
study
aims
enroll
approximately
patients
study
md
anderson
study
dose
escalation
trial
evaluate
combination
cord
nk
cells
adult
patients
recurrent
refractory
lymphomas
primary
objective
study
establish
safety
recommended
phase
dose
cbnk
cells
followed
weekly
treatment
intravenous
secondary
objectives
include
assessing
overall
complete
partial
response
rates
details
study
found
using
identifier
bispecific
innate
cell
engager
induces
specific
selective
killing
tumor
cells
engaging
activating
natural
killer
nk
cells
macrophages
thereby
leveraging
power
innate
immune
system
affimed
advanced
clinical
program
currently
evaluated
monotherapy
trial
patients
relapsed
refractory
peripheral
lymphoma
redirect
study
actively
recruiting
found
using
identifier
affimed
affimed
nasdaq
afmd
company
committed
giving
patients
back
innate
ability
fight
cancer
affimed
platform
allows
innate
cell
engagers
designed
specific
patient
populations
company
developing
single
combination
therapies
treat
hematologic
solid
tumors
company
currently
enrolling
patients
study
relapsed
refractory
peripheral
cell
lymphoma
phase
dose
escalation
expansion
study
treatment
advanced
solid
tumors
information
please
visit
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
appear
number
places
throughout
release
include
statements
regarding
intentions
beliefs
projections
outlook
analyses
current
expectations
concerning
among
things
potential
value
platform
ongoing
planned
preclinical
development
clinical
trials
collaborations
development
products
combination
therapies
timing
ability
make
regulatory
filings
obtain
maintain
regulatory
approvals
product
candidates
intellectual
property
position
collaboration
activities
ability
develop
commercial
functions
clinical
trial
data
results
operations
cash
needs
financial
condition
liquidity
prospects
future
transactions
growth
strategies
industry
operate
trends
may
affect
industry
us
impacts
pandemic
benefits
affimed
orphan
drug
designation
risks
uncertainties
factors
described
heading
risk
factors
affimed
filings
securities
exchange
commission
given
risks
uncertainties
factors
place
undue
reliance
statements
assume
obligation
update
statements
even
new
information
becomes
available
future
investor
media
contact
alex
fudukidis
head
investor
relations
email
tel
